Search

A recent study conducted at University Sultan Zainal Abidin in Malaysia explored the association between osteoporosis and chronic obstructive pulmonary disease (COPD) in male patients. The study found that COPD patients had lower levels of Osteoprotegerin (OPG), leading to increased bone resorption and lower bone mineral density, particularly in patients with severe COPD. The research highlighted the importance of assessing bone health in COPD patients to prevent osteoporosis-related complications. [Extracted from the article]

A study conducted in Kemerovo, Russia, focused on analyzing the prevalence of prefrailty and frailty syndrome in patients with coronary artery disease undergoing elective percutaneous coronary intervention (PCI). The research included 78 patients with CAD, and findings indicated a high prevalence of prefrailty (33.3%) and frailty syndrome (24.4%) in this population. Older women with type 2 diabetes were more likely to be frail, and lower levels of calcitonin and osteoprotegerin, along with higher levels of leptin, were associated with frail patients before PCI. The study utilized a variety of biological markers to assess inflammation and musculoskeletal and fat remodeling in these patients. [Extracted from the article]

Researchers from Wuhan University in China conducted a study on the role of TGF-beta signaling in promoting the expression of osteoprotegerin (OPG) in cementoblasts to inhibit osteoclastogenesis, which is relevant to orthodontic tooth treatment. The study found that TGF-beta 1-induced Smads and AP-1 can bind to the OPG promoter, leading to increased OPG expression and secretion, ultimately protecting cementum from excessive resorption. This research sheds light on the molecular mechanisms underlying orthodontically induced root resorption and offers insights into potential therapeutic strategies. [Extracted from the article]

A report from Guangdong University of Technology discusses research findings on the ultrasensitive and visual detection of osteoprotegerin using a rotation microfluidic device for ELISA on paper. The study highlights the importance of efficient osteoprotegerin detection in clinical settings, overcoming current diagnostic limitations. The innovative method utilizes a rotating paper-based microfluidic chip with a modified ELISA colorimetric technique, offering a portable point-of-care solution with low cost, operational simplicity, stability, and high sensitivity. This research has been peer-reviewed and provides a promising avenue for improved OPG analysis. [Extracted from the article]

The article discusses the interaction between osteoprotegerin (OPG) and fibulin-1 in the context of idiopathic pulmonary fibrosis (IPF), a fatal lung disease. The study found a positive correlation between OPG and fibulin-1 levels in patients with IPF, suggesting a potential complex formation between the two proteins. The research indicates that OPG, fibulin-1, and latent TGF{beta} binding protein 1 (LTBP1) may form a complex in the extracellular environment, potentially regulating the deposition of extracellular matrix in lung tissue. [Extracted from the article]

A recent study from the University of Sao Paulo (USP) explores the association between osteoprotegerin and RANKL single nucleotide polymorphisms and destructive rhinosinusitis in patients with granulomatosis with polyangiitis (GPA). The research suggests that SNPs in osteoprotegerin G1181C and RANKL A290G may contribute to the development of destructive rhinosinusitis in GPA patients. This observational study could pave the way for further research and clinical trials focusing on RANKL/osteoprotegerin as potential therapeutic targets. [Extracted from the article]

Recent studies from Nanjing University have shown that interleukin-13 can reduce bone erosion in rheumatoid arthritis by up-regulating osteoprotegerin expression in fibroblast-like synoviocytes. This research, funded by various organizations including the National Natural Science Foundation of China, highlights the potential of IL-13 to inhibit osteoclastogenesis and ameliorate bone destruction in RA. The study, which has been peer-reviewed, provides valuable insights into the mechanisms underlying IL-13's therapeutic effects in rheumatoid arthritis. [Extracted from the article]

A study conducted at Mustansiriyah University in Baghdad, Iraq, examined the association of periodontitis with serum osteoprotegerin levels in postmenopausal type 2 diabetic women. The research found that periodontal parameters and serum osteoprotegerin levels were significantly higher in diabetic women, particularly those with poor glycemic control, compared to healthy controls. The study also revealed a positive correlation between serum osteoprotegerin levels and probing pocket depth in all groups studied. This peer-reviewed research provides valuable insights into the relationship between periodontitis and diabetes in postmenopausal women. [Extracted from the article]

The article discusses a clinical trial, NCT06646705, focusing on the impact of orthodontic treatment with aligners on changes in osteoprotegerin (OPG) and receptor activator of NF-kB ligand (RANKL) levels in saliva samples. The study involves 25 systemically healthy non-smoking individuals undergoing orthodontic treatment with aligners, with periodontal clinical parameters measured before and after treatment. Enzyme-linked immunosorbent assay (ELISA) is used to analyze OPG and RANKL levels in saliva samples. The trial is being conducted at Izmir Katip Celebi University in Turkey. [Extracted from the article]

Researchers at Women's College Research Institute in Toronto, Canada have conducted a study on the relationship between circulating osteoprotegerin (OPG) and bone health in women with a pathogenic variant in the BRCA1 gene. OPG is known to play a role in inhibiting bone resorption. The study found that women with lower levels of OPG may be at a higher risk for skeletal bone loss and lower bone mineral density. Further research is needed to better understand this association. The study was funded by Canada Excellence Research Chairs. [Extracted from the article]

A recent study conducted at the King Faisal Specialist Hospital and Research Center has found that the osteoprotegerin (OPG) cytokine, which plays a role in bone homeostasis, has both pro- and anti-carcinogenic effects in breast cancer. The study showed that OPG promotes pro-metastatic processes, stemness, angiogenesis, and the activation of breast stromal fibroblasts. Additionally, OPG upregulation was found to enhance the resistance of luminal breast cancer cells to certain chemotherapeutic drugs, while OPG downregulation sensitized triple-negative breast cancer cells to these drugs. The study concludes that OPG promotes stemness and chemoresistance in breast cancer cells. [Extracted from the article]

A recent study conducted at Federal University Rio Grande do Norte in Brazil has found that caffeine consumption can lead to alveolar bone loss in rats undergoing orthodontic movement. The study involved 25 male Wistar rats, with one group receiving caffeine and the other serving as the control. The rats in the caffeine group exhibited lower bone volume and increased inflammatory infiltrate compared to the control group. The researchers concluded that caffeine induces alveolar bone loss through the activation of specific signaling pathways. This research provides new insights into the effects of caffeine on bone metabolism. [Extracted from the article]

A recent study conducted by researchers at the Department of Neurosurgery and Interventional Neuroradiology in Hiroshima, Japan, explored the relationship between osteoprotegerin (OPG) expression and aneurysm wall integrity in unruptured intracranial aneurysms (UIAs). The study found that UIAs with high levels of OPG expression had thicker aneurysm walls and higher levels of transforming growth factor beta 1 (TGF-beta 1) compared to UIAs with low OPG expression. Additionally, UIAs with aneurysm growth had relatively higher OPG expression. The study suggests that OPG may play a role in protective remodeling and the retention of aneurysm wall structures. [Extracted from the article]

A preprint abstract from medrxiv.org discusses the role of osteoprotegerin (OPG) and its ligands RANKL and TRAIL in falciparum, vivax, and knowlesi malaria. The study found that OPG levels were increased in Malaysian adults with falciparum and vivax malaria, while RANKL and TRAIL levels were decreased in proportion to disease severity. In volunteers infected with P. falciparum and P. vivax, RANKL was suppressed and TRAIL was unexpectedly increased. The study also demonstrated that P. falciparum stimulates B cells to produce OPG, and B cell OPG production is increased in patients with falciparum, vivax, and knowlesi malaria. The findings suggest the importance of the OPG/RANKL/TRAIL pathway in diseases involving systemic inflammation and may have implications for adjunctive therapies. [Extracted from the article]

A recent study conducted at the University of Bielsko-Biala in Poland explored the relationship between osteoprotegerin (OPG) and angiotensin II (Ang II) in mice. The study found that OPG plays a crucial role in the development of endothelial dysfunction induced by Ang II. Mice lacking OPG showed preserved endothelial function after exposure to Ang II, while mice with OPG exhibited significant endothelial dysfunction. The absence of OPG also resulted in a decrease in pro-inflammatory cytokines in the vascular wall after Ang II exposure. These findings suggest that OPG is essential for the development of Ang II-induced inflammation and endothelial dysfunction. [Extracted from the article]

Researchers from Pomeranian Medical University in Szczecin, Poland have conducted a study on peritoneal dialysis and its relation to osteoprotegerin (OPG) and chronic inflammation. The study included 37 patients undergoing peritoneal dialysis therapy, and the researchers found that both plasma and dialysate OPG levels were associated with the severity of systemic and local inflammation. This suggests that OPG may play a significant role in explaining the presence of inflammation in peritoneal dialysis patients. The study provides valuable insights into the relationship between OPG and inflammation in this context. [Extracted from the article]

A recent study conducted at Wroclaw University of Science and Technology in Poland explores the relationship between osteopontin (OPN) and osteoprotegerin (OPG) in the regulation of tissue biomineralization. The researchers conducted quantitative and qualitative analyses of OPN and OPG content in aorta sections and performed an enzyme-linked immunosorbent assay (ELISA) test to determine collagen and elastin content. The study found correlations between OPN or OPG and various types of collagen and elastin content, suggesting that these glycoproteins have different tissue localizations and independent expression regulation. The findings contribute to a better understanding of the role of extracellular matrix proteins in calcifying arteries. [Extracted from the article]

A clinical trial, NCT06349135, has been launched to assess the serum concentration of Interleukin-17 and Osteoprotegerin in response to surgical trauma induced by the management of mandibular fractures. The study aims to compare the outcomes of intraoral versus extraoral approaches in the treatment of mandibular fractures. The trial is observational and will follow patients for a duration of 6 weeks. The study is not yet recruiting participants, and the estimated completion date is December 15, 2025. [Extracted from the article]

Researchers from Cairo University have conducted a study on the relationship between serum osteoprotegerin levels and endothelial dysfunction in obese non-diabetic individuals. The study found that obese subjects had higher rates of insulin resistance and dyslipidemia compared to controls. Serum osteoprotegerin levels were significantly lower in obese subjects, and there was a positive correlation between osteoprotegerin and insulin resistance. The researchers suggest that osteoprotegerin could be a serum biomarker for predicting insulin resistance in obese individuals. [Extracted from the article]

A recent study conducted in Bandung, Indonesia, explored the correlation between serum levels of osteoprotegerin (OPG) and transferrin saturation in patients with transfusion-dependent thalassemia (TDT). Osteoporosis is a common issue in TDT patients, and OPG is a glycoprotein associated with osteoporosis. The study found a significant inverse correlation between OPG and transferrin saturation levels in TDT patients. This research provides valuable insights into the relationship between these markers and may contribute to the understanding and management of osteoporosis in TDT patients. [Extracted from the article]

A recent study conducted at the Catholic University of Korea explored the effects of stepwise administration of osteoprotegerin (OPG) and parathyroid hormone-related peptide (PTHrP) DNA vectors on bone formation in an ovariectomized rat model of osteoporosis. The researchers found that the combined treatment with OPG and PTHrP significantly increased osteogenic marker expression in osteoblast differentiation compared to the single treatment groups. The study concluded that stepwise treatment with OPG and PTHrP may be a potential treatment for osteoporosis, as it significantly improved bone microstructure in the rat model. Further research is needed to explore this treatment option. [Extracted from the article]

A recent study conducted by researchers at Alexandria University explored the potential markers of preclinical rheumatoid arthritis (RA) in first-degree relatives (FDRs) of RA patients. The study found that FDRs of RA patients had altered bone metabolism, as indicated by higher levels of Osteoprotegerin (OPG) and lower levels of Osteopontin (OPN) compared to healthy controls. Musculoskeletal ultrasound (MSUS) was also used to detect subclinical joint inflammation in FDRs. The researchers concluded that OPN and OPG could serve as markers of altered preclinical bone metabolism in FDRs of RA, and that the US7 score from MSUS could be a useful screening tool for identifying individuals at risk of developing RA. [Extracted from the article]

A study conducted by Istanbul University explores the relationship between peroxisome proliferator-activated receptor gamma (PPAR-g) and osteoprotegerin (OPG) levels as indicators and diagnostic predictors of endothelial dysfunction. The researchers aimed to understand the connection between PPAR-g Pro12Ala, OPG, and PPAR-g in Peripheral Vascular Disease (PVD) and hypertension (HT). Additionally, they investigated the relationship between flow-mediated dilatation (FMD) in HT and ankle brachial index (ABI) in PVD in terms of endothelial dysfunction (ED). The study provides valuable insights into the cellular processes contributing to atherosclerosis and related conditions. [Extracted from the article]

Researchers from Universitas Brawijaya in Malang, Indonesia have conducted a study on the effects of Pangasius djambal gelatin on bone resorption. The study aimed to investigate the expressions of osteoprotegerin (OPG), receptor activator nuclear factor-b (RANK), and its ligand (RANKL) following tooth extraction. The researchers found that the application of P. djambal gelatin increased OPG expression and decreased RANKL and RANK expression, suggesting that it may inhibit bone resorption. This research provides valuable insights into potential treatments for bone diseases and conditions. [Extracted from the article]

A recent study conducted in Fujian, People's Republic of China, investigated the action mechanism of denshensu in treating glucocorticoid-induced osteoporosis (GIOP). The study involved 60 rats divided into different groups, including a control group, model group, estradiol group, and denshensu treatment group. The results showed that denshensu significantly enhanced the micro-structure of bone trabeculae, bone mineral density, and bone metabolic markers, while reducing trabecular separation and structural model index. Additionally, denshensu inhibited the differentiation of positive osteoclasts and reduced osteoclast-related genes. The study concluded that denshensu may inhibit the expressions of osteoprotegerin (OPG) and receptor activator of nuclear factor-kappa B ligands (RANKL), thus playing a role in treating GIOP. [Extracted from the article]

A recent study conducted at Wuhan Fourth Hospital in China explored the effect of osteoprotegerin (OPG) on osteoblasts (OB) and arteriosclerosis (AS). The researchers prepared a nanocomplex called Poly(ethylene glycol)-Poly(L-Lysine)-Osteoprotegerin (PPO) and observed its effects on bone mineral density (BMD) and arteriosclerosis in mice. The study found that PPO enhanced OB activity, inhibited cell apoptosis, promoted cell calcification and adhesion, and reduced the area of atherosclerotic plaque and calcification. PPO also increased BMD and reduced arterial plaque area and vascular calcification. This research suggests that PPO may have potential therapeutic applications in the treatment of arteriosclerosis. [Extracted from the article]

A recent study conducted by researchers at Pomeranian Medical University in Szczecin, Poland, explored the role of the Osteoprotegerin (OPG) gene in the development of osteoporosis in postmenopausal Polish women. The study analyzed the influence of specific polymorphisms of the OPG gene on the risk of osteoporosis and osteopenia. The researchers found a statistically significant association between the OPG rs207361 polymorphism and the risk of osteoporosis, suggesting that this variant may be a genetic marker associated with the pathogenesis of osteoporosis. This research provides valuable insights into the genetic factors contributing to metabolic bone diseases and may contribute to the development of diagnostic and screening tools for osteoporosis. [Extracted from the article]

A systematic review with meta-analysis conducted by researchers at Hanzhong Central Hospital in Shanxi, China, examined the association between osteoprotegerin (OPG) and receptor activator of nuclear factor kappa-B ligand (RANKL) with osteoporosis. The study found that while the serum levels of OPG and RANKL were not significantly associated with osteoporosis, the OPG/RANKL ratio was lower in the osteoporosis group compared to the control group. The researchers concluded that OPG and RANKL are important factors in bone formation and resorption, and standardizing test methods and units would be beneficial for clinical applications. [Extracted from the article]

A recent study conducted by researchers at Rijeka University Hospital Center in Croatia explored the relationship between chronic kidney disease (CKD) and bone metabolism disorders. The study aimed to identify markers of bone turnover in patients with CKD, including those who had received kidney transplants. The researchers found that serum osteoprotegerin (OPG) levels increased as kidney function declined, with the highest levels observed in the dialysis group. They also discovered that OPG levels were lower in patients who had undergone dialysis for less than four years prior to transplantation. The study concluded that CKD-mineral and bone disorder begins in stage 3 CKD, and an increase in OPG levels in stage 2 CKD may be an early sign of this disorder. Additionally, longer dialysis vintage (more than four years) was associated with more significant disturbances in mineral and bone metabolism. [Extracted from the article]

A report from Hannover Medical School in Germany provides pediatric reference values for soluble receptor activator of nuclear factor kappa B ligand (sRANKL) and osteoprotegerin (OPG), which are regulators of bone metabolic turnover in children. The study generated LMS-based continuous reference percentiles for sRANKL, OPG, and the sRANKL/OPG ratio, which are age-dependent and associated with sex. The research concludes that these reference values can be used to calculate standardized patient z-scores to assess bone modeling in children. This is the first report of its kind and can contribute to improved data interpretation in clinical practice. [Extracted from the article]

Keywords: Nagoya; Japan; Asia; Biological Factors; Colony Stimulating Factors; Connective Tissue Cells; Cytokines; Enzymes and Coenzymes; Fibroblasts; Genetics; Glycoproteins; Health and Medicine; Hematopoietic Cell Growth Factors; Immunology; Intercellular Signaling Peptides and Proteins; Kinase; Macrophage Colony-Stimulating Factor; Macrophages; Mononuclear Phagocyte System; Myeloid Cells; Osteoblasts; Osteoprotegerin; Peptides; Phagocytes; Proteins; Tumor Necrosis Factor Decoy Receptors EN Nagoya Japan Asia Biological Factors Colony Stimulating Factors Connective Tissue Cells Cytokines Enzymes and Coenzymes Fibroblasts Genetics Glycoproteins Health and Medicine Hematopoietic Cell Growth Factors Immunology Intercellular Signaling Peptides and Proteins Kinase Macrophage Colony-Stimulating Factor Macrophages Mononuclear Phagocyte System Myeloid Cells Osteoblasts Osteoprotegerin Peptides Phagocytes Proteins Tumor Necrosis Factor Decoy Receptors 3036 3036 1 11/06/23 20231110 NES 231110 2023 NOV 10 (NewsRx) -- By a News Reporter-Staff News Editor at Health & Medicine Week -- A new study on Intercellular Signaling Peptides and Proteins - Hematopoietic Cell Growth Factors is now available. For more information on this research see: Resveratrol Inhibits Basic Fibroblast Growth Factor-induced Macrophage Colony-stimulating Factor Synthesis Via the Pi3-kinase/akt Pathway In Osteoblasts. [Extracted from the article]

Keywords: Little Rock; State:Arkansas; United States; North and Central America; Bone Research; Health and Medicine; Immunology; Macrophages; Osteoblasts; Osteoclasts; Osteocytes; Osteoprotegerin; Risk and Prevention; Tumor Necrosis Factor Decoy Receptors EN Little Rock State:Arkansas United States North and Central America Bone Research Health and Medicine Immunology Macrophages Osteoblasts Osteoclasts Osteocytes Osteoprotegerin Risk and Prevention Tumor Necrosis Factor Decoy Receptors 2705 2705 1 11/06/23 20231110 NES 231110 2023 NOV 10 (NewsRx) -- By a News Reporter-Staff News Editor at Health & Medicine Week -- Fresh data on Immunology - Tumor Necrosis Factor Decoy Receptors are presented in a new report. According to news originating from Little Rock, Arkansas, by NewsRx correspondents, research stated, "Denosumab is an anti-RANKL Ab that potently suppresses bone resorption, increases bone mass, and reduces fracture risk. [Extracted from the article]

Blood Pressure, Cardiology, Cardiovascular, Cardiovascular Diseases and Conditions, Cardiovascular Research, Diabetes Mellitus, Endocrine System Diseases and Conditions, Endocrinology, Genetics, Glucose Metabolism Disorders, Health and Medicine, Heart Rate, Hemodynamics, Hypertension, Immunology, Metabolic Diseases and Conditions, Non-Insulin Dependent Diabetes Mellitus, Nutritional and Metabolic Diseases and Conditions, Osteoprotegerin, Risk and Prevention, Tumor Necrosis Factor Decoy Receptors, Type 2 Diabetes Keywords: Blood Pressure; Cardiology; Cardiovascular; Cardiovascular Diseases and Conditions; Cardiovascular Research; Diabetes Mellitus; Endocrine System Diseases and Conditions; Endocrinology; Genetics; Glucose Metabolism Disorders; Health and Medicine; Heart Rate; Hemodynamics; Hypertension; Immunology; Metabolic Diseases and Conditions; Non-Insulin Dependent Diabetes Mellitus; Nutritional and Metabolic Diseases and Conditions; Osteoprotegerin; Risk and Prevention; Tumor Necrosis Factor Decoy Receptors; Type 2 Diabetes EN Blood Pressure Cardiology Cardiovascular Cardiovascular Diseases and Conditions Cardiovascular Research Diabetes Mellitus Endocrine System Diseases and Conditions Endocrinology Genetics Glucose Metabolism Disorders Health and Medicine Heart Rate Hemodynamics Hypertension Immunology Metabolic Diseases and Conditions Non-Insulin Dependent Diabetes Mellitus Nutritional and Metabolic Diseases and Conditions Osteoprotegerin Risk and Prevention Tumor Necrosis Factor Decoy Receptors Type 2 Diabetes 999 999 1 10/30/23 20231031 NES 231031 2023 OCT 30 (NewsRx) -- By a News Reporter-Staff News Editor at Hematology Week -- Researchers detail new data in type 2 diabetes. [Extracted from the article]

Keywords: Cardiovascular Diseases and Conditions; Health and Medicine; Hypertension; Immunology; Osteoprotegerin; Tumor Necrosis Factor Decoy Receptors EN Cardiovascular Diseases and Conditions Health and Medicine Hypertension Immunology Osteoprotegerin Tumor Necrosis Factor Decoy Receptors 175 175 1 10/24/23 20231023 NES 231023 2023 OCT 23 (NewsRx) -- By a News Reporter-Staff News Editor at Cardiovascular Week -- New research on hypertension is the subject of a new report. Cardiovascular Diseases and Conditions, Health and Medicine, Hypertension, Immunology, Osteoprotegerin, Tumor Necrosis Factor Decoy Receptors. [Extracted from the article]

Keywords: Huzhou; People's Republic of China; Asia; Alendronate; Chronic Obstructive Pulmonary Disease; Diphosphonates; Health and Medicine; Immunology; Lung Diseases and Conditions; Metabolic Bone Diseases and Conditions; Musculoskeletal Diseases and Conditions; Osteoporosis; Osteoprotegerin; Pulmonary Disease; Tumor Necrosis Factor Decoy Receptors EN Huzhou People's Republic of China Asia Alendronate Chronic Obstructive Pulmonary Disease Diphosphonates Health and Medicine Immunology Lung Diseases and Conditions Metabolic Bone Diseases and Conditions Musculoskeletal Diseases and Conditions Osteoporosis Osteoprotegerin Pulmonary Disease Tumor Necrosis Factor Decoy Receptors 2017 2017 1 10/16/23 20231020 NES 231020 2023 OCT 20 (NewsRx) -- By a News Reporter-Staff News Editor at Health & Medicine Week -- Data detailed on Lung Diseases and Conditions - Chronic Obstructive Pulmonary Disease have been presented. Huzhou, People's Republic of China, Asia, Alendronate, Chronic Obstructive Pulmonary Disease, Diphosphonates, Health and Medicine, Immunology, Lung Diseases and Conditions, Metabolic Bone Diseases and Conditions, Musculoskeletal Diseases and Conditions, Osteoporosis, Osteoprotegerin, Pulmonary Disease, Tumor Necrosis Factor Decoy Receptors. [Extracted from the article]

Arthritis, Autoimmune Diseases and Conditions, Biomarkers, Diagnostics and Screening, Health and Medicine, Immunology, Joint Diseases and Conditions, Musculoskeletal Diseases and Conditions, Osteoprotegerin, Rheumatoid Arthritis, Tumor Necrosis Factor Decoy Receptors Keywords: Arthritis; Autoimmune Diseases and Conditions; Biomarkers; Diagnostics and Screening; Health and Medicine; Immunology; Joint Diseases and Conditions; Musculoskeletal Diseases and Conditions; Osteoprotegerin; Rheumatoid Arthritis; Tumor Necrosis Factor Decoy Receptors EN Arthritis Autoimmune Diseases and Conditions Biomarkers Diagnostics and Screening Health and Medicine Immunology Joint Diseases and Conditions Musculoskeletal Diseases and Conditions Osteoprotegerin Rheumatoid Arthritis Tumor Necrosis Factor Decoy Receptors 4780 4780 1 09/25/23 20230929 NES 230929 2023 SEP 29 (NewsRx) -- By a News Reporter-Staff News Editor at Health & Medicine Week -- Current study results on rheumatoid arthritis have been published. [Extracted from the article]

Keywords: Nova Friburgo; Brazil; South America; Blood Proteins; Clinical Research; Cytokines; Drugs and Therapies; Extracellular Matrix Proteins; Glycoproteins; Health and Medicine; Immunology; Intercellular Signaling Peptides and Proteins; Membrane Proteins; Monokines; Mouth Diseases and Conditions; Osteopontin; Osteoprotegerin; Peptides; Periodontal Diseases and Conditions; Periodontitis; Proteins; Receptor Activator of Nuclear Factor-kappa B; Risk and Prevention; Tumor Necrosis Factor Decoy Receptors; Tumor Necrosis Factor Receptors; Tumor Necrosis Factor-alpha; Tumor Necrosis Factors EN Nova Friburgo Brazil South America Blood Proteins Clinical Research Cytokines Drugs and Therapies Extracellular Matrix Proteins Glycoproteins Health and Medicine Immunology Intercellular Signaling Peptides and Proteins Membrane Proteins Monokines Mouth Diseases and Conditions Osteopontin Osteoprotegerin Peptides Periodontal Diseases and Conditions Periodontitis Proteins Receptor Activator of Nuclear Factor-kappa B Risk and Prevention Tumor Necrosis Factor Decoy Receptors Tumor Necrosis Factor Receptors Tumor Necrosis Factor-alpha Tumor Necrosis Factors 1865 1865 1 08/28/23 20230901 NES 230901 2023 SEP 1 (NewsRx) -- By a News Reporter-Staff News Editor at Drug Week -- Current study results on Periodontal Diseases and Conditions - Periodontitis have been published. Nova Friburgo, Brazil, South America, Blood Proteins, Clinical Research, Cytokines, Drugs and Therapies, Extracellular Matrix Proteins, Glycoproteins, Health and Medicine, Immunology, Intercellular Signaling Peptides and Proteins, Membrane Proteins, Monokines, Mouth Diseases and Conditions, Osteopontin, Osteoprotegerin, Peptides, Periodontal Diseases and Conditions, Periodontitis, Proteins, Risk and Prevention, Tumor Necrosis Factor Decoy Receptors, Tumor Necrosis Factor Receptors, Tumor Necrosis Factor-alpha, Tumor Necrosis Factors, Receptor Activator of Nuclear Factor-kappa B. [Extracted from the article]

Keywords: Gothenburg; Sweden; Europe; Health and Medicine; Immunology; Orthodontics; Osteoprotegerin; Tumor Necrosis Factor Decoy Receptors EN Gothenburg Sweden Europe Health and Medicine Immunology Orthodontics Osteoprotegerin Tumor Necrosis Factor Decoy Receptors 6128 6128 1 08/21/23 20230825 NES 230825 2023 AUG 25 (NewsRx) -- By a News Reporter-Staff News Editor at Health & Medicine Week -- A new study on Immunology - Tumor Necrosis Factor Decoy Receptors is now available. Keywords for this news article include: Gothenburg, Sweden, Europe, Health and Medicine, Immunology, Orthodontics, Osteoprotegerin, Tumor Necrosis Factor Decoy Receptors, University of Gothenburg. Gothenburg, Sweden, Europe, Health and Medicine, Immunology, Orthodontics, Osteoprotegerin, Tumor Necrosis Factor Decoy Receptors. [Extracted from the article]

Biomarkers, Bone Diseases and Conditions, Clinical Research, Clinical Trials and Studies, Cytokines, Diagnostics and Screening, Drugs and Therapies, Estradiol Congeners, Estradiol Therapy, Estrogens, Gonadal Hormones, Health and Medicine, Hormone Replacement Therapy, Immunology, Intercellular Signaling Peptides and Proteins, Interleukin-6, Interleukins, Light Metals, Magnesium, Musculoskeletal Diseases and Conditions, Osteoprotegerin, Peptides, Pharmaceuticals, Proteins, Sex Hormones, Spinal Diseases and Conditions, Spinal Osteophytosis, Tumor Necrosis Factor Decoy Receptors, Vaginal Agents, Vaginal Preparations, Spondylosis Keywords for this news article include: National Orthopaedic Hospital, Pharmaceuticals, Cytokines, Estrogens, Magnesium, Biomarkers, Immunology, Spondylosis, Light Metals, Sex Hormones, Interleukin-6, Vaginal Agents, Osteoprotegerin, Gonadal Hormones, Clinical Research, Estradiol Therapy, Drugs and Therapies, Estradiol Congeners, Health and Medicine, Spinal Osteophytosis, Vaginal Preparations. [Extracted from the article]

Keywords: Lianyungang; People's Republic of China; Asia; Autacoids; Biological Factors; Bone Morphogenetic Protein; Bone Morphogenetic Protein 7; Bone Morphogenetic Proteins; Bone Research; Eicosanoids; Health and Medicine; Immunology; Inflammation Mediators; Intercellular Signaling Peptides and Proteins; Osteoprotegerin; Peptides; Radius Fracture; Surgery; TGF-beta Superfamily Proteins; Thromboxane A2; Thromboxanes; Tumor Necrosis Factor Decoy Receptors EN Lianyungang People's Republic of China Asia Autacoids Biological Factors Bone Morphogenetic Protein Bone Morphogenetic Protein 7 Bone Morphogenetic Proteins Bone Research Eicosanoids Health and Medicine Immunology Inflammation Mediators Intercellular Signaling Peptides and Proteins Osteoprotegerin Peptides Radius Fracture Surgery TGF-beta Superfamily Proteins Thromboxane A2 Thromboxanes Tumor Necrosis Factor Decoy Receptors 5969 5969 1 08/14/23 20230818 NES 230818 2023 AUG 18 (NewsRx) -- By a News Reporter-Staff News Editor at Health & Medicine Week -- Investigators discuss new findings in Radius Fracture. Between January 2021 and January 2022, a total of 124 patients (71 males, 53 females; mean age: 49.8 & PLUSMN;5.1 years; range, 34 to 68 years) with distal radius fractures were included in the fracture group." For more information on this research see: Predictive Value of Bone Morphogenetic Protein-7, Thromboxane A2, and Osteoprotegerin for Prognosis of Patients With Distal Radius Fractures. [Extracted from the article]